Biohaven Ltd.'s SEC filings document the formal disclosures of a British Virgin Islands clinical-stage biopharmaceutical company listed under BHVN. The filing record includes Form 8-K reports for operating results, Regulation FD presentations, clinical and regulatory pipeline updates, and material equity financing events involving common shares.
Proxy and annual-meeting filings cover director elections, auditor ratification, executive compensation votes and shareholder governance matters. Registration-related disclosures and prospectus supplements describe shelf registration mechanics, at-the-market equity distribution arrangements, underwriting agreements and common-share issuance activity that support the company's development-stage funding strategy.
Suvretta Capital Management and affiliates reported significant ownership stakes in Biohaven Ltd. common shares as of 12/31/2025. Suvretta Capital Management, LLC and its principal, Aaron Cowen, each beneficially own 10,286,937 common shares, representing 7.8% of the class, with shared voting and dispositive power over these shares.
Averill Master Fund, Ltd., an advisory client of Suvretta, directly owns 8,800,438 common shares, equal to 6.6% of the class, also with shared voting and dispositive power. All securities in this amendment are directly owned by Suvretta advisory clients, and the reporting persons state that the holdings are not for the purpose of changing or influencing control of Biohaven.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 16,803,459 common shares of Biohaven Ltd., representing 12.7% of the class as of the triggering event on 01/30/2026.
The shares are held across multiple investment advisers and their client accounts, referred to as Managed Portfolios. Janus Henderson’s asset managers share voting and investment power over these Biohaven shares, while the Managed Portfolios themselves receive all dividends and sale proceeds. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Biohaven.
Biohaven Ltd. disclosed that it will be making an investor presentation on January 12, 2026. The company has prepared an investor slide deck, described as an Investor Presentation dated January 2026, and made it available as an exhibit to this report so that the broader market has access to the same information shared with investors.
The presentation materials are furnished for informational purposes only under Regulation FD, meaning they are not treated as formally filed financial statements or incorporated into other securities law documents unless specifically referenced in the future.
Biohaven Ltd. senior vice president of clinical operations Kimberly Gentile reported routine equity transactions tied to restricted share units. On January 5, 2026, 3,750 restricted share units converted into the same number of common shares at an exercise price of $0, increasing her directly held stake. To cover tax withholding on this vesting, 1,956 common shares were withheld by the company at a price of $9.93 per share, with no shares sold into the market. After these transactions, Gentile directly owned 99,557 common shares and held 7,500 restricted share units, which represent the right to receive additional common shares as future vesting dates are met.
Biohaven Ltd. Chief Financial Officer Matthew Buten reported equity award activity and related tax withholding on common shares. On January 5, 2026, 4,250 restricted share units were exercised at an effective price of $0, delivering the same number of common shares. To cover taxes due on this vesting, 2,594 common shares were withheld by Biohaven at a price of $9.93 per share, and no shares were sold into the market.
After these transactions, Buten directly beneficially owned 195,652 common shares, which includes 544 shares acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025. He also held 8,500 restricted share units following the reported transaction, each representing the right to receive one common share, with the original 17,000-unit grant vesting in four annual installments through January 5, 2028, subject to continued service.
Biohaven Ltd. Chief Executive Officer and director Vlad Coric reported routine equity compensation activity. On January 5, 2026, 14,250 restricted share units vested and were converted into 14,250 common shares at $0 per share. On the same date, 7,430 common shares were withheld by Biohaven at $9.93 per share to cover tax obligations, and no shares were sold into the market.
Following these transactions, Coric directly holds 1,803,968 common shares and 28,500 restricted share units. Additional common shares are held indirectly through a family trust, a marital trust and a 401(k) plan. The family and marital trust positions are for the benefit of family members other than Coric, and he disclaims beneficial ownership of those securities.
Biohaven Ltd. Chief Scientific Officer Car Bruce reported equity award activity and updated holdings. On January 5, 2026, 4,750 restricted share units converted into an equal number of common shares at an exercise price of $0, reflecting a scheduled vesting from a prior grant.
To cover taxes on this vesting, 2,381 common shares were withheld by Biohaven at $9.93 per share rather than sold on the market. After these transactions, Car Bruce directly owns 7,715 common shares, which include 544 shares acquired through the company’s employee share purchase plan, and indirectly holds 30,000 common shares through an IRA. The original restricted share unit grant was 19,000 units awarded on January 5, 2025, vesting in four equal annual installments through 2028, with 9,500 units remaining outstanding after this vesting.
Biohaven Vice President and Chief Accounting Officer George C. Clark reported the vesting and conversion of 2,500 restricted share units into common shares on January 5, 2026. To satisfy taxes, 1,117 shares were withheld by the issuer at $9.93 per share rather than sold in the market. After these transactions, he owns 66,978 common shares directly and 20,000 common shares indirectly through an IRA. The RSUs are part of a 10,000-unit grant from January 5, 2025 that vests in four equal annual installments.
Biohaven Ltd. agreed to issue and sell 12,500,000 common shares to Janus Henderson Investors at a purchase price of $10.00 per share. The company expects to receive approximately $125 million in gross proceeds upon settlement, before fees and other expenses. These new shares are being issued as a block transaction under Biohaven’s existing “at-the-market” offering program, which is registered on Form S-3 and described in a prospectus dated October 2, 2023 and a prospectus supplement dated August 16, 2024.
Biohaven Ltd. officer reports open-market share purchase. A vice president and Chief Accounting Officer of Biohaven Ltd. (BHVN) bought 17,000 common shares on 11/17/2025 at a weighted average price of $8.5159 per share through a series of trades within a narrow price range. After this transaction, the insider beneficially owns 20,000 common shares indirectly through an IRA and 65,595 shares directly, for a combined personal stake in the company that includes 544 shares acquired under the employee share purchase plan.